Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603264 | 0.90 | HCRTR2 (0.45) | HTTTDP1KMT2AMEN1CYP2C19 | |
| SCHEMBL2606065 | 0.82 | ALDH1A1 (0.49) | HTTTDP1KMT2AMEN1TPSAB1 | |
| SCHEMBL13107150 | 0.82 | KMT2A (0.64) | HTTKMT2AMEN1CNR1CNR2 | |
| SCHEMBL2603259 | 0.81 | KMT2A (0.42) | HTTTDP1KMT2ACYP2C19LMNA | |
| SCHEMBL2603258 | 0.80 | HCRTR2 (0.48) | HTTTDP1KMT2AMEN1CYP2C19 | |
| SCHEMBL24474332 | 0.79 | KMT2A (0.46) | HTTKMT2ACYP2C19HCRTR2LMNA | |
| SCHEMBL2603262 | 0.78 | TDP1 (0.43) | HTTTDP1KMT2ACYP2C19HCRTR2 | |
| SCHEMBL20034735 | 0.77 | PTGS1 (0.40) | HTTKMT2AMEN1CNR1CNR2 | |
| SCHEMBL26228168 | 0.76 | KMT2A (0.43) | HTTKMT2AMEN1CYP2C19HCRTR2 | |
| SCHEMBL8251062 | 0.75 | RAB9A (0.52) | HTTKMT2AMEN1CYP2C19TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | HTT 1695/4885TDP1 1457/4885KMT2A 2032/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | HTT 699/4885TDP1 643/4885KMT2A 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.